Evidence map›Paper›PMID 41547674›Full record

ReviewDiscover oncology2026

Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.

Sina Sadati, Sara Yazdizadeh, Seyed Mohsen Razavi, Mina Homayoonfal, Gordon A Ferns, Fatemeh Divani, Hamed Mirzaei

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sina SadatiStudent Research Committee, Kashan University of Medical Sciences, Kashan, Iran.
Sara YazdizadehStudent Research Committee, Kashan University of Medical Sciences, Kashan, Iran. yazdizadehsarah@gmail.com.
Seyed Mohsen RazaviMedical Oncologist and Hematologist, Iran Medical Science University, Firouzgar Teaching Hospital, Tehran, Iran.
Mina HomayoonfalResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Gordon A FernsBrighton and Sussex Medical School, Division of Medical Education, Brighton, UK.
Fatemeh DivaniDepartment of Rheumatology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. fatemehdivani@gmail.com.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. H.mirzaei2002@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of cancers, their economic impact and the complications associated with existing treatments, have stimulated research to better understand the mechanisms involved in their aetiology and the development of more effective diagnostic and treatment methods. Olverembatinib (HQP1351 or GZD824) is a new third-generation tyrosine kinase inhibitor (TKI), that is being investigated for its potential application in the treatment of several cancers, with a focus on chronic myeloid leukemia (CML). This review attempts to summarise the pre-clinical and clinical studies in hematological and non-hematological malignancies of this agent.

Indexed as

CancerGZD824Hematologic malignancyHQP1351OlverembatinibTKITyrosine kinase inhibitor

Identifiers

PMID41547674
PMCPMC12894599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.